WATCH LIVE
timothy sykes logo
GKOS Jumps As Glaukos Wins Target Hikes On Epioxa Thumbnail
G Google News

GKOS Jumps As Glaukos Wins Target Hikes On Epioxa

JACK KELLOGG•UPDATED JUL. 4, 2026, 10:09 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Glaukos Corporation stocks have been trading up by 7.84 percent following upbeat glaucoma treatment trial news boosting investor optimism.

What Traders Need To Know

  • Citi raised its Glaukos price target from $140 to $162 and reiterated a Buy rating, citing a substantial and underappreciated growth runway for its Epioxa product.
  • Needham raised its Glaukos price target from $136 to $150 and reiterated a Buy rating, expecting the Epioxa launch to become a significant growth driver by 2027 and partially offset potential LCD reimbursement risk for iDose.
  • Glaukos completed patient enrollment of 275 US patients in its placebo-controlled Phase 2 trial of GLK-321 cream for Demodex blepharitis, evaluating three dose levels with a primary endpoint of eliminating collarettes after six weeks.
  • Analysts broadly maintain an average Buy rating on Glaukos, with a mean price target of $157.50.
  • Recent amended Form 4/A filings updated insider beneficial ownership records, appearing as routine governance disclosures.

Candlestick Chart

Weekly Update Jun 29 – Jul 03, 2026: On Saturday, July 04, 2026 Glaukos Corporation stock [NYSE: GKOS] is trending up by 7.84%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Glaukos holds a leading niche in micro-invasive glaucoma surgery and is extending into corneal and ocular-surface therapeutics, supporting durable mid‑20s revenue growth (three- and five-year CAGRs of 24% and 18%). Gross margin at 57.6% is robust, but EBIT margin of roughly -35% and ROE near -26% highlight a scale and investment phase. Balance sheet quality is a clear strength: debt-to-equity of 0.15, current ratio 5.4, and $276M in cash and investments provide ample runway despite negative free cash flow.

Technically, GKOS remains in a strong primary uptrend, with repeated closes above $137 and rapid recovery to $148.35, confirming aggressive dip-buying. Recent 5-minute action shows tight intraday ranges and constructive consolidations rather than distribution, consistent with institutional support. A key actionable trading level is $138–140: as long as price holds above this zone on normal volume, long positions are favored, with stops just below $135 to manage downside risk.

Fundamentally, near-term catalysts are compelling: phase 2 completion of GLK-321 enrollment expands the iLution ocular-surface pipeline, while Epioxa is emerging as the next major growth driver per Citi and Needham, both lifting targets into the $150–162 range. Relative to Healthcare and MedTech peers, GKOS trades at a premium price-to-sales (~15x) justified by superior growth and underpenetrated indications. I expect continued outperformance, with near-term resistance at $150 and a 12–18 month upside target of $160.

More Breaking News

Quick Financial Overview

Glaukos Corporation (GKOS) sits in a classic high-growth, high-valuation lane. Revenue over the last year was about $507.4M, with three-year growth above 24% and five-year growth above 18%. Despite that top-line strength, GKOS is still losing money, with profit margins around -34% and negative returns on equity and assets. For short-term traders, that means sentiment, pipeline headlines, and analyst calls will often move the stock more than earnings multiples.

The balance sheet is a positive anchor in the story. Glaukos carries total liabilities of roughly $222.4M against equity near $670.9M and long-term debt of about $103.1M, leading to a modest debt-to-equity ratio of 0.15. Liquidity is strong, with a current ratio around 5.4 and quick ratio near 4.4, backed by cash and short-term investments of about $276.7M. Operating cash flow last quarter was negative at about -$12.5M, and free cash flow was around -$16.5M, showing the business is still in a heavy investment phase.

On the tape, GKOS has shown active buying interest. The most recent intraday bar captured a wide range from about $136.2 up to $148.6, closing near $148.3, which signals strong demand into strength rather than profit-taking. Weekly data show price lifting from the mid-$130s to the high-$140s, with closes stepping higher from roughly $137.6 to $148.3. Combined with multiple price-target hikes and progress on GLK-321 and Epioxa, the current action looks like momentum building on a bullish news cluster rather than a random spike.

Conclusion

Glaukos Corporation now has a clear narrative that traders can map: strong top-line growth, a deepening eye-care pipeline, and a Street that keeps walking targets higher. Citi moving its GKOS target to $162 and Needham to $150, against a mean target around $157.50, shows broad confidence that Epioxa could become a major revenue engine and help offset reimbursement risk around iDose. At the same time, the completed Phase 2 enrollment for GLK-321 pushes the ocular surface story forward, adding another potential driver if data cooperate.

The other side of the coin is just as important. GKOS still runs negative margins and negative free cash flow, which means any stumble in clinical data, pricing, or reimbursement can hit the stock hard. The high price-to-sales multiple, around 15x, tells you expectations are already rich. Short-term traders should respect that: strength can extend when the news flow stays bullish, but pullbacks can be sharp when sentiment flips. The recent push from the mid-$130s into the high-$140s sets that zone as a first support band to watch on any reversal. As I tell my students, “In names like GKOS, you trade the reaction to catalysts, not the story in your head — let the price, volume, and news alignment be your trigger, not your hope.” As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.”.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”